Drugs / narsoplimab
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT05855083 | May 2023 → Dec 2025 overdue | disease related to hematopoietic stem cell transplant, thrombotic microangiopathy | Omeros Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT04488081 | Jul 2020 → Jul 2028 expected | COVID-19 | QuantumLeap Healthcare Collaborative | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02682407 | Mar 2016 → Aug 2020 | IgA glomerulonephritis, complement 3 glomerulopathy | Omeros Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT02222545 | Nov 2014 → Jan 2020 | thrombotic microangiopathy | Omeros Corporation | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03205995 | May 2018 → Feb 2021 | atypical hemolytic-uremic syndrome | Omeros Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT03608033 | Apr 2018 → Jan 2024 | IgA glomerulonephritis | Omeros Corporation | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02355782 | — | thrombotic microangiopathy | Michal Nowicki | Available | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04247906 Background | — | thrombotic microangiopathy | Omeros Corporation | Approved for marketing | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | narsoplimab | “The purpose of this study is to evaluate the efficacy and safety of narsoplimab (OMS721) compared to placebo on proteinuria and whether narsoplimab has the ability to slow...” NCT03608033 ↗4“Narsoplimab (OMS721), an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), was evaluated for safety and efficacy in adults with HSCT-TMA.” PMID 35439028 ↗ Apr 2022 |
| Known as | Masp-2 antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298195 ↗ |
| Known as | OMS00620646 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298195 ↗ |
| Known as | OMS620646 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298195 ↗ |
| Known as | OMS721 | “Narsoplimab (OMS721), an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), was evaluated for safety and efficacy in adults with HSCT-TMA.” PMID 35439028 ↗ Apr 2022 |
| Action | Inhibit | “an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)” PMID 35439028 ↗ Apr 2022 |
| Modality | Monoclonal antibody | “Human IgG4 MASP-2 Monoclonal Antibody” NCT02355782 ↗ |
| Route | Intravenous | “patients received intravenous narsoplimab once weekly for 4-8 weeks” PMID 35439028 ↗ Apr 2022 |
| Target | MASP2 | “an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)” PMID 35439028 ↗ Apr 2022 |